Business
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Working to advance TSC-related epilepsy program, with a focus on capital efficiencyAUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, and other diseases associated with dy
About this update from Filana Therapeutics, Inc.
[{"type":"image","alt":"Filana Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Filana Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/ec6f71a08700bedee385c3d7ccb26ead"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uZkjHJLQMvSlKYdHiR28zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ec6f71a08700bedee385c3d7ccb26ead","width":300,"height":300}},"lazy":false},{"type":"text","content":"Working to advance TSC-related epilepsy program, with a focus on capital efficiency","length":83,"tagName":"p"},{"type":"text","content":"AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a business update.","length":582,"tagName":"p"},{"type":"text","content":"Net loss for 2025 was $91.0 million, or $1.88 per share, compared to a net loss of $24.3 million, or $0.53 per share (basic), in 2024. Net cash used in operations was $32.3 million in 2025, consistent with previous guidance.","length":224,"tagName":"p"},{"type":"text","content":"The Company met cash guidance for year-end 2025, reporting $95.5 million, and estimates cash at June 30, 2026 in a range from $47 to $50 million. The Company estimates net cash use in operations for first half of 2026 in a range from $14 to $17 million, plus a payment of a $31.25 million estimated loss contingency related to the potential settlement of certain securities litigation recorded in 2025.","length":402,"tagName":"p"},{"type":"text","content":"“At Filana Therapeutics, our name reflects our deep commitment to science and to patients affected by diseases tied to filamin A dysregulation, including TSC-related epilepsy. We are driven by the urgent need for new treatment options that can meaningfully improve patients’ lives,” said Rick Barry, President and ...